產(chǎn)品目錄

規(guī)格	10 mM * 1 mL in DMSO 5mg 10mg
CAS	957118-49-9
別名	MK3207;MK 3207
化學(xué)名	2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide
分子式	C31H29F2N5O3
分子量	557.59
溶解度	Soluble in DMSO
儲存條件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request

產(chǎn)品描述：

MK-3207 is a new, highly selective CGRP receptor antagonist that is approximately 40- to 65-fold more potent than telcagepant for the human CGRP receptor. The IC50 is 0.12 nM and The Ki value is 0.024 nM. It is highly selective versus human AM1, AM2, CTR, and AMY3. [1]

Calcitonin gene-related peptide (CGRP) is a 37 amino acid neuropeptide that is widely distributed in the central and peripheral nervous system. The CGRP receptor is composed of the calcitonin receptor-like receptor (CLR), a family B G protein-coupled receptor (GPCR), in association with receptor activity modifying protein 1 (RAMP1) and receptor component protein. A number of lines of evidence implicated CGRP in migraine pathophysiology, and this led to interest in the potential utility of CGRP receptor antagonists as novel therapeutics for migraine. [2]

MK-3207 displayed high affinity for the native human CGRP receptor in SK-N-MC cells and for the recombinant human receptor as measured by the ability to compete with 125I-hCGRP binding, with Ki values of 0.024 ± 0.001 nM and 0.022 ± 0.002 nM, respectively. MK-3207 displayed a similar affinity (Ki) for the rhesus monkey receptor (0.024 ± 0.001 nM) as for human, but it displayed 400-fold lower affinity for the canine and rat receptors, with values of 10 nM and 10 ± 1.2 nM , respectively. MK-3207 potently blocked human α-CGRP-stimulated cAMP responses in human CGRP receptor-expressing HEK293 cells, with an IC50 value of 0.12 ±0.02 nM . Addition of 50% human serum (IC50 =0.17 ± 0.02nM) had little effect on the apparent potency ofMK-3207. [3]

MK-3207 has EC50 and Emax values of approximately 0.8 ± 0.3 nM (mean ± S.E.) and 81 ± 5% (mean ± S.E.), respectively, for inhibition of CIDV in rhesus monkeys. The expected EC90 value in rhesus monkey is therefore approximately 7 nM (9-fold higher than the estimated EC50 value). After an oral dose of 10 mg/kg MK-3207, the CSF/plasma ratio is 2 to 3% . However, the CSF/ plasma ratio is approximately 30% of the unbound fraction (9.4%) in plasma, indicating that the central and peripheral compartments are not freely equilibrating.

特別提醒：

1. 本產(chǎn)品僅供科研使用。請勿用于醫(yī)藥、臨床診斷或治療，食品及化妝品等用途。請勿存放于普通住宅區(qū)。

2. 為了您的安全和健康，請穿好實驗服并佩戴一次性手套和口罩操作。

原創(chuàng)作者：上海莼試生物技術(shù)有限公司

在線咨詢

留言注意事項：

1.遵守中華人民共和國有關(guān)法律、法規(guī)，尊重網(wǎng)上道德，承擔(dān)一切因您的行為而直接或間接引起的法律責(zé)任。

2.請您真實的反映產(chǎn)品的情況,不要捏造、誣蔑、造謠。如對產(chǎn)品有任何疑問,也可以留言咨詢。

3.未經(jīng)本站同意，任何人不得利用本留言簿發(fā)布個人或團體的具有廣告性質(zhì)的信息或類似言論。

您感興趣的產(chǎn)品*
您的單位*
聯(lián)系人*
聯(lián)系電話*
詳細(xì)地址*
常用郵箱*
請輸入您對我們的意見或建議*
驗證碼*